Takeda Pharmaceutical
310 hedge funds and large institutions have $1.32B invested in Takeda Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 90 increasing their positions, 97 reducing their positions, and 28 closing their positions.
647% more call options, than puts
Call options by funds: $44.7M | Put options by funds: $5.98M
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
46% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 28
3% more funds holding
Funds holding: 300 → 310 (+10)
0.2% less ownership
Funds ownership: 5.5% → 5.31% (-0.2%)
4% less capital invested
Capital invested by funds: $1.38B → $1.32B (-$60.3M)
7% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 97
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$20.9M |
| 2 |
Jane Street
New York
|
+$15.4M |
| 3 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
+$14.2M |
| 4 |
Renaissance Technologies
New York
|
+$11.1M |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$9.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$53.5M |
| 2 |
Barclays
London,
United Kingdom
|
-$26.8M |
| 3 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$26M |
| 4 |
Millennium Management
New York
|
-$12.4M |
| 5 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$11.1M |
TAK Hedge Fund Activity: Q2 2023 in Review
310 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2023, worth a combined $1.32B — down 4.4% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new TAK positions and 28 closed out — a net gain of 13 holders — while 90 added to existing stakes and 97 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $20.9M. The largest seller was Envestnet Asset Management, cutting an estimated $53.5M.
- 310 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2023, up from 300 in Q1 2023.
- Funds reported $1.32B of Takeda Pharmaceutical stock for Q2 2023, down 4.4% quarter-over-quarter.
- 41 funds opened new Takeda Pharmaceutical positions in Q2 2023 and 28 closed out, a net change of +13 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2023 was Arrowstreet Capital, an estimated $20.9M added.
- The largest Takeda Pharmaceutical seller in Q2 2023 was Envestnet Asset Management, an estimated $53.5M sold.
Based on aggregated 13F filings for Q2 2023.